跳至主要内容
临床试验/NCT01477307
NCT01477307已完成不适用

Effect of Dietary Intervention on Intestinal Microbiota in Patients With Non-alcoholic Fatty Liver Disease

University Hospital, Geneva1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2013年7月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
abundance of fecal abundance of fecal Bacteroidetes

研究概览

简要总结

In patients with NAFLD/NASH, changes in liver lipid composition and function tests following a short dietary intervention are associated with changes in gut microbiota

详细描述

Study Hypothesis: In patients with NAFLD/NASH, changes in liver lipid composition and function tests following a short dietary intervention are associated with changes in gut microbiota

Study period:

  • Study duration for the participant: 7-10 weeks (1-4 weeks screening period, 3 weeks of intervention + 3 weeks of follow-up)
  • Expected study completion date: 30.04.2012 Study type: Single arm before-after study

Number of patients:

20 subjects with obesity and NAFLD / NASH

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Obesity defined as BMI>30 Abnormal liver function tests defined as ALT > 1.5 times the upper limit of normal NAFLD present at liver biopsy Age > 18 years, < 60 years

排除标准

  • Inability or unwillingness to give consent Bulimia Other known cause of chronic liver disease, including hepatitis B or C, iron overload, Use of substances known to alter intestinal permeability, including alcohol and NSAIDs

结局指标

主要结局

abundance of fecal abundance of fecal Bacteroidetes

时间窗: thrice, at inclusion, day 21 and day 42

Bacterial cells/g caecal content

次要结局

  • body composition(thrice, at inclusion, day 21 and day 42)
  • Breath test pullulation(twice, at inclusion and day 21)
  • serum LPS(twice, at inclusion and day 21)
  • intestinal permeability(twice, at inclusion and day 21)
  • liver fat content(twice, at inclusion and day 21)
  • liver function tests(four times, at screening, inclusion, day 21 and day 42)
  • CRP(thrice, at screening, inclusion and day 21)
  • serum cytokines(twice, at inclusion and day 21)
  • liver lipid composition (biopsy)(once, at screening)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Claude Pichard

Head, Clinical Nutrition

University Hospital, Geneva

研究点 (1)

Loading locations...

相似试验